Evercore ISI Reaffirms Their Sell Rating on AN2 Therapeutics, Inc. (ANTX)

TipRanks00:45 ET · Ratings

AN2 Therapeutics Price Target Maintained With a $5.00/Share by Citizens Capital Markets

Dow JonesFeb 25 10:42 ET · Ratings

Optimistic Buy Rating for AN2 Therapeutics Driven by Strong Phase 2 Results and Strategic FDA Alignment

TipRanksFeb 24 12:35 ET · Ratings

Express News | AN2 Therapeutics Inc: To Release Topline Phase 3 Results for Ebo-301 in Q2 of 2025

ReutersFeb 24 07:15 ET

AN2 Therapeutics Submits Amended EBO-301 Trial Statistical Analysis Plan to FDA

TipRanksFeb 24 07:15 ET

Express News | AN2 Therapeutics Advances Phase 3 EBO-301 Trial Wih PRO-Based QOL-B Endpoint, Setting Stage For Potential Registrational Pathways

BenzingaFeb 24 07:08 ET